Newsroom

Sorted by: Latest

-

KBRA Assigns Preliminary Ratings to Fidelis Mortgage Trust 2026-RTL2 (FIDL 2026-RTL2)

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to FIDL 2026-RTL2, a $191.5 million revolving RMBS transaction issued by Fidelis Investors Mortgage Fund I, LP (Fidelis), as seller/sponsor, and backed by Residential Transition Loans (RTLs). The transaction is the sponsor's fourth rated securitization backed by RTL collateral, and KBRA’s first rated RTL transaction. The collateral consists entirely of RTLs purchased by Fidelis from either its affiliated originator, Unitas Funding LLC...
-

Resumen: Teva y Polpharma Biologics anuncian un acuerdo de licencia internacional para un candidato a biosimilar de Ocrevus® (ocrelizumab) para la esclerosis múltiple

TEL AVIV, Israel, y ZUG, Suiza--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, filial de Teva Pharmaceutical Industries Ltd (NYSE: y TASE: TEVA), y Polpharma Biologics International AG han anunciado hoy un acuerdo de licencia internacional que otorga a Teva los derechos exclusivos para comercializar ambas formulaciones del biosimilar propuesto por Polpharma Biologics para Ocrevus®1 (ocrelizumab), una vez obtenida la autorización reglamentaria. El comunicado en el idioma original es l...
-

ALIGNMENT HEALTHCARE, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ:ALHC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 8, 2026, it was reported that a former executive at Alignment Healthcare fil...
-

Samenvatting: Teva en Polpharma Biologics kondigen een globale licentieovereenkomst aan voor een biosimilair kandidaatgeneesmiddel voor Ocrevus® (ocrelizumab) ter behandeling van multiple sclerose

TEL AVIV, Israël & ZUG, Zwitserland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, een dochteronderneming van Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA), en Polpharma Biologics International AG kondigden vandaag een globale licentieovereenkomst aan die Teva exclusieve rechten verschaft om beide formules van Polpharma Biologics’ voorgestelde biosimilaire geneesmiddel voor Ocrevus®1 (ocrelizumab) op de markt te brengen, onder voorbehoud van wettelijke goedkeuring. Deze...
-

Gurobi führt den „Intelligence Hub“ ein und bringt KI-gesteuerte Arbeitsabläufe in den gesamten Optimierungszyklus

BEAVERTON, Ore.--(BUSINESS WIRE)--Gurobi Optimization, LLC, der Anbieter im Bereich Decision-Intelligence-Technologie, gab heute die Einführung des Gurobi Intelligence Hub bekannt – der neuen Plattform für Gurobis KI-gestützte Optimierungsagenten. Der Intelligence Hub soll Anwender:innen dabei helfen, Optimierungsmodelle effektiver zu erstellen, zu verstehen, mit ihnen zu arbeiten und Fehler in ihnen zu beheben. Die spezialisierten Experten des Hubs nutzen gemeinsam generative KI, um Anwender d...
-

Nano Dimension Board Sets the Record Straight on Murchinson's Self-Interested and Destructive Campaign

WALTHAM, Mass.--(BUSINESS WIRE)--Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano,” or the “Company”) today issued the following letter to shareholders regarding its upcoming Extraordinary General Meeting (“EGM”) scheduled for July 31, 2026. Nano's Board of Directors (the “Board”) urges shareholders to carefully evaluate its recommendations and vote accordingly. Dear Fellow Shareholders: The upcoming Extraordinary General Meeting centers on a fundamental question: should Murchinson L...
-

Teva et Polpharma Biologics annoncent la signature d’un accord de licence mondial portant sur un candidat biosimilaire à l’Ocrevus® (ocrelizumab) destiné au traitement de la sclérose en plaques

TEL AVIV, Israël et ZOUG, Suisse--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, filiale de Teva Pharmaceutical Industries Ltd. (NYSE : et TASE : TEVA), et Polpharma Biologics International AG ont annoncé aujourd’hui la conclusion d’un accord de licence mondial accordant à Teva les droits exclusifs de commercialisation des deux formulations du médicament biosimilaire proposé par Polpharma Biologics pour l’Ocrevus®1 (ocrelizumab), sous réserve de l’obtention des autorisations réglemen...
-

Allegion Schedules Webcast to Announce 2026 Second-Quarter Results

DUBLIN--(BUSINESS WIRE)--Allegion plc (NYSE: ALLE), a leading global security products and solutions provider, will release its 2026 second-quarter financial results on Thursday, July 23, before the market opens. Later that morning, John H. Stone, president and CEO, and Mike Wagnes, senior vice president and chief financial officer, will conduct a conference call for analysts and investors, beginning at 8 a.m. ET, to review the company's results. The real-time webcast and a replay of the event...
-

Resumen: NIPPON KINZOKU acelera las ventas internacionales de las tiras de acero eléctrico ultrafinas de las «GT Series» y las «ST Series» como productos respetuosos con el medio ambiente bajo la marca «Fine Eco Metal»

TOKIO--(BUSINESS WIRE)--NIPPON KINZOKU CO., LTD. (Sede central: Minato-ku, Tokio; presidente: Yasushi Shimokawa; TOKIO: 5491) y su filial, NIKKIN DENJI KOGYO CO., LTD. (sede central: Kawaguchi, Saitama; presidente: Akira Nishimura), lanzan una iniciativa comercial estratégica para sus bandas de acero eléctrico ultrafinas orientadas (GT Series) y no orientadas (ST Series) bajo la marca «Fine Eco Metal». «Fine Eco Metal» es el nombre comercial de nuestra línea exclusiva «Eco-Product», certificada...
-

Report van Orca Security: 99,9% van de oplosbare AI-kwetsbaarheden blijft onopgelost nu AI naar productie overstapt

PORTLAND, Ore.--(BUSINESS WIRE)--Orca Security, een leider in cloud- en AI-beveiliging, publiceerde vandaag zijn 2026 State of AI Security Report, waarin een zicht uit eerste hand wordt geboden op de manier waarop AI in meer dan 1.200 productiecloudomgevingen geïntegreerd wordt. De bevindingen tonen aan dat AI niet langer tot geïsoleerde pilootprojecten of experimenten van ontwikkelaars is beperkt. Organisaties integreren AI in productietoepassingen, cloudservices en autonome workflows sneller...